Showing results (951-960 of 997) with videos related to

Sort By:
Pageof 100
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 31, 2026
Exploring longitudinal relationships among Alzheimer's disease biomarkersBenjamin Saef, Kellen K Petersen, Katherine Volluz, et al.
Medrxiv : the Preprint Server for Health Sciences|July 15, 2024
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsNoëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, et al.
Brain : a Journal of Neurology|October 29, 2024
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsNoëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, et al.
Nature Communications|June 19, 2015
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumoursMadhuri Kalathur, Alberto Toso, Jingjing Chen, et al.
European Journal of Radiology|July 19, 2025
Overview of different reimbursement strategies among contrast-enhanced mammography (CEM) expert centers on a global level - A survey studyJavier Azcona Sáenz, Pascal A T Baltzer, Iris Allajbeu, et al.
Prostate Cancer and Prostatic Diseases|November 6, 2023
External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extensionJ G Heetman, E J R J van der Hoeven, P Rajwa, et al.
JAMA Neurology|February 10, 2025
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based BiomarkersLawren VandeVrede, Hanna Cho, Mark Sanderson-Cimino, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 21, 2026
Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [18F]MK6240Arthur C Macedo, Karine Provost, Jean-Paul Soucy, et al.
Annals of Neurology|June 20, 2025
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET ClocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Ebiomedicine|September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled studyOlivier Sol, Julien Mermoud, Merja Hallikainen, et al.
Pageof 100